News | September 09, 2009

Abiomed Showcases Impella Technology at TCT 2009

September 9, 2009 – Abiomed Inc. said today its percutaneous Impella ventricular assist device will be highlighted in several clinical sessions at the upcoming TCT 2009 scientific meeting Sept. 21-25, in San Francisco.

Abiomed will also conduct daily booth demonstrations at Abiomed booth 1230 and hands-on simulations of its heart recovery platforms. The company will also broadcast daily live feeds of Impella cases from the TCT line-up of live case broadcasts. In addition, the Abiomed booth will feature physicians presenting challenging cases using Impella 2.5.

On Monday, Sept. 21 the company will host “Device-Based Approaches for Heart Failure: Recent Developments and New Directions?Session V: Acute Hemodynamic Support Devices” in room 132 at the Moscone Convention Center. Sessions involving the Impella are at:
• 2:50 – 3:02 p.m. “Circulatory Support in STEMI: Intra-aortic Balloon Counterpulsation vs. Impella,” presented by Jose P.S. Henriques, M.D., Ph.D., Academic Medical Center, University of Amsterdam
• 3:02 – 3:14 p.m. – “The Impella 5.0 Device: Surgical and Cardiogenic Shock Applications,” presented by Anson Cheung, M.D. clinical associate professor, surgical director, cardiac transplant program of BC Active Staff, St. Paul's Hospital Vancouver
• 3:14 – 3:26 p.m. – “Results from USpella, the first registry presentation on the U.S. commercial Impella experience with over 100 patients,” presented by Brijeshwar Maini, M.D., cochair, cardiovascular research, interventional cardiologist, Pinnacle Health; attending cardiologist, Moffitt Heart & Vascular Group
• 3:26 – 3:38 p.m. – “Continuum in Circulatory Support to Recover the Failing Heart: How and When to Escalate from Percutaneous to Surgical VADs,” presented by Mark Anderson, M.D., associate professor of surgery at UMDNJ-Robert Wood Johnson Medical School and chief of the section of cardiac surgery at Robert Wood Johnson University Hospital

On Tuesday, Sept. 22 Abiomed will host an investor and analyst meeting from 4-5 p.m. in 22?room Golden Gate 4, Hilton San Francisco. The meeting will provide a 40-minute overview and update on Impella progress, followed by a 20-minute forum for questions and open discussion. To register, contact Aimee Maillett at [email protected] or (978) 646-1553.

Abiomed will host an evening symposium – “Hemodynamic Principles to Patient Application”?– Tuesday, Sept. 22, in the Imperial Ballroom, Hilton San Francisco. There is a cocktail reception from 7-8 p.m., followed by the symposium from 8-10 p.m. It is chaired by William O’Neill, M.D., executive dean for clinical affairs at the University of Miami. This is a customer event and participation for noncustomers is subject to availability and Abiomed discretion. Noncustomers must request attendance by contacting Aimee Maillett at [email protected] or (978) 646-1553. Speakers include: John Lasala, M.D., Ph.D., medical director of the cardiac cath lab, associate professor of medicine and director of interventional cardiology at Barnes-Jewish Hospital; Samin Sharma, M.D., director of the cath lab and interventions, Mount Sinai Medical Center; Jose P.S. Henriques, M.D., Ph.D., Academic Medical Center, University of Amsterdam.

On Wednesday, Sept. 23 is a breakfast session, “Impella 2.5 - Case Reviews of Real World Application,” in 23?room 114 A, Moscone Convention Center. Breakfast is?6:30–7 a.m. and the session is from 7–8 a.m. It is chaired by Charanjit S. Rihal, M.D., director of the cardiac cath lab and professor of medicine, Mayo Clinic.

Another breakfast session, “Impella 2.5 - Hemodynamic Support in High Risk PCI and Cardiogenic Shock: A Case-Based Review”? will be held Friday, Sept. 25 in?room 114, Moscone Convention Center. ?It will focus on a new fellow scholarship program where fellows present their best Impella cases to their peers, called, “International Fellows Awarded Best Impella Case of the Year,” chaired by Roxana Mehran, M.D., director of outcomes research, data coordination and analysis, associate professor of medicine, New York-Presbyterian Hospital/Columbia University Medical Center and director of clinical research, data coordination and analysis center at the Cardiovascular Research Foundation.

For additional information: www.abiomed.com

Related Content

Medtronic Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
Technology | Ventricular Assist Devices (VAD) | July 17, 2018
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for a less-invasive implant approach...
CorWave's Next-generation Neptune LVAD Receives Funding

Image courtesy of CorWave

News | Ventricular Assist Devices (VAD) | July 11, 2018
French-based CorWave announced that its CALYPSO program has received 14 million euros to develop CorWave Neptune, a new...
Abbott Recalls the HeartMate 3 Left Ventricular Assist System, LVAD
News | Ventricular Assist Devices (VAD) | May 23, 2018
Abbott has initiated a Class I recall of the HeartMate 3 Left Ventricular Assist System due to a malfunction in the...
FDA Approves Abiomed Impella CP With SmartAssist and Optical Sensor
Technology | Ventricular Assist Devices (VAD) | April 02, 2018
Abiomed Inc. announced that it received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its...
Reduced Device Clotting, Decreased Strokes Seen With HeartMate 3 at Two Years
News | Ventricular Assist Devices (VAD) | March 13, 2018
At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully...
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD) | October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD) | September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD) | August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD) | June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Overlay Init